Citadel Advisors’s BeOne Medicines Ltd ONC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.44M | Sell |
8,200
-6,800
| -45% | -$2.2M | ﹤0.01% | 5675 |
|
|
2025
Q4 | $4.56M | Buy |
15,000
+3,100
| +26% | +$1.01M | ﹤0.01% | 4428 |
|
|
2025
Q3 | $4.05M | Sell |
11,900
-2,800
| -19% | -$850K | ﹤0.01% | 4735 |
|
|
2025
Q2 | $3.56M | Buy |
14,700
+4,300
| +41% | +$1.05M | ﹤0.01% | 4687 |
|
|
2025
Q1 | $2.83M | Buy |
10,400
+400
| +4% | +$93.5K | ﹤0.01% | 4877 |
|
|
2024
Q4 | $1.85M | Buy |
10,000
+8,500
| +567% | +$1.74M | ﹤0.01% | 5797 |
|
|
2024
Q3 | $337K | Sell |
1,500
-2,400
| -62% | -$432K | ﹤0.01% | 9080 |
|
|
2024
Q2 | $556K | Buy |
3,900
+1,700
| +77% | +$262K | ﹤0.01% | 7840 |
|
|
2024
Q1 | $344K | Sell |
2,200
-6,100
| -73% | -$982K | ﹤0.01% | 9181 |
|
|
2023
Q4 | $1.5M | Sell |
8,300
-6,900
| -45% | -$1.25M | ﹤0.01% | 5895 |
|
|
2023
Q3 | $2.73M | Buy |
15,200
+4,400
| +41% | +$871K | ﹤0.01% | 4650 |
|
|
2023
Q2 | $1.93M | Buy |
10,800
+3,200
| +42% | +$737K | ﹤0.01% | 5212 |
|
|
2023
Q1 | $1.64M | Sell |
7,600
-13,200
| -63% | -$3.17M | ﹤0.01% | 5747 |
|
|
2022
Q4 | $4.57M | Buy |
20,800
+11,300
| +119% | +$2.07M | ﹤0.01% | 3994 |
|
|
2022
Q3 | $1.28M | Buy |
9,500
+4,900
| +107% | +$842K | ﹤0.01% | 6466 |
|
|
2022
Q2 | $745K | Sell |
4,600
-14,300
| -76% | -$2.23M | ﹤0.01% | 7710 |
|
|
2022
Q1 | $3.56M | Buy |
18,900
+1,800
| +11% | +$383K | ﹤0.01% | 4836 |
|
|
2021
Q4 | $4.63M | Sell |
17,100
-3,600
| -17% | -$1.22M | ﹤0.01% | 4446 |
|
|
2021
Q3 | $7.51M | Buy |
20,700
+14,000
| +209% | +$4.58M | ﹤0.01% | 3560 |
|
|
2021
Q2 | $2.3M | Sell |
6,700
-3,700
| -36% | -$1.23M | ﹤0.01% | 6247 |
|
|
2021
Q1 | $3.62M | Sell |
10,400
-6,000
| -37% | -$1.99M | ﹤0.01% | 5005 |
|
|
2020
Q4 | $4.24M | Buy |
16,400
+9,200
| +128% | +$2.53M | ﹤0.01% | 3956 |
|
|
2020
Q3 | $2.06M | Buy |
7,200
+1,100
| +18% | +$259K | ﹤0.01% | 4651 |
|
|
2020
Q2 | $1.15M | Sell |
6,100
-400
| -6% | -$65.1K | ﹤0.01% | 5576 |
|
|
2020
Q1 | $800K | Sell |
6,500
-46,600
| -88% | -$7.29M | ﹤0.01% | 5709 |
|
|
2019
Q4 | $8.8M | Buy |
53,100
+43,600
| +459% | +$7.24M | ﹤0.01% | 2339 |
|
|
2019
Q3 | $1.16M | Sell |
9,500
-43,800
| -82% | -$5.82M | ﹤0.01% | 5331 |
|
|
2019
Q2 | $6.61M | Buy |
53,300
+44,900
| +535% | +$5.7M | ﹤0.01% | 2707 |
|
|
2019
Q1 | $1.11M | Sell |
8,400
-2,300
| -21% | -$310K | ﹤0.01% | 5401 |
|
|
2018
Q4 | $1.5M | Sell |
10,700
-14,000
| -57% | -$1.86M | ﹤0.01% | 4628 |
|
|
2018
Q3 | $4.25M | Buy |
24,700
+2,600
| +12% | +$437K | ﹤0.01% | 3207 |
|
|
2018
Q2 | $3.4M | Buy |
+22,100
| New | +$3.94M | ﹤0.01% | 3300 |
|
Other funds holding ONC
BBA
HA
SL
Citadel Advisors's ONC Position: Q1 2026 in Review
Citadel Advisors increased its BeOne Medicines Ltd (ONC) stake by 93% in Q1 2026, buying an estimated $161M and bringing the position to 1,032,298 shares worth $307M. The position accounts for 0.05% of the portfolio, ranked #305.
Citadel Advisors first reported a position in ONC in Q2 2018 and has held it in 31 quarters since. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.
- Citadel Advisors held 1,032,298 shares of BeOne Medicines Ltd worth $307M as of Q1 2026.
- Citadel Advisors bought 498,781 BeOne Medicines Ltd shares in Q1 2026, an estimated $161M.
- BeOne Medicines Ltd made up 0.05% of Citadel Advisors's portfolio in Q1 2026, its #305 holding.
- Citadel Advisors first reported a position in BeOne Medicines Ltd in Q2 2018 and has held it in 31 quarters since.
- 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.